CYFWY yields 12.38% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, CYFWY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CYFWY + JNJ for your $10,000?
Cyfrowy Polsat S.A. provides digital satellite platform and terrestrial television (TV), and telecommunication services in Poland. The company offers satellite and Internet pay television, mobile and fixed-line telephony, mobile and fixed-line broadband Internet access, wholesale, and TV broadcasting and production services, as well as online content, news, and video sharing services. It offers approximately 150 TV channels, including terrestrial, general entertainment, sports and e-sports, music, lifestyle, news/information, children's, education, and movie channels; and over the top services, such as Cyfrowy Polsat GO, VOD/PPV, online video and music, catch-up TV, and multiroom HD services. In addition, the company provides database of legal video content and live broadcasts; online TV channels; live coverages of sports events; and feature films, and TV series and programs. Further, it offers telecommunications, software, retail, radio and TV, media, call center and premium rate, technical, advertising, Web portals, monetary intermediation, sponsorship, broadcasting and signal transmission, premises and facilities leasing, and other financial services; produces broadcasting, television, and electronic equipment; produces, leases, and sells set-top boxes; and sells licenses, sublicenses, and property rights, as well as STB hard disk drives, antennas, Internet modems, tablets, laptops, routers, TV sets, accessories, and other devices. The company was formerly known as Polsat Cyfrowy S.A. and changed its name to Cyfrowy Polsat S.A. in 2004. Cyfrowy Polsat S.A. was incorporated in 1996 and is headquartered in Warsaw, Poland.
Full CYFWY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.